Lonza Group AG stock (CH0013841017): focus shifts to growth after strategic review and margin reset

Endpoints NewsRegeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Lonza NewsBristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement - CHEManager

Endpoints NewsFDA approves AstraZeneca’s baxdrostat for certain patients with hypertension

FierceBiotechIpsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3

Ningbo HEALTH Gene Technologies Co., Ltd.$1 Billion Human Identification Market Analysis by Product, Technology, Application, End User and Region - Forecast to 2031 - Yahoo! Finance Canada

FierceBiotechAnalysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial

BioPharma DiveUnlocking more value from mature drug products through strategic outsourcing

GCCGCC Hydroxypropyl Methylcellulose Market Report 2026–2034 | Construction and Pharma Trends - vocal.media

FierceBiotechArdent Health taps Fujifilm’s AI-enabled patient imaging platform

FierceBiotechExecuting biomarker-driven oncology trials

10x Genomics NewsAssessing 10x Genomics (TXG) Valuation After Q1 2026 Results And Rising AI Trading Interest - simplywall.st

Lonza NewsLonza Group AG stock (CH0013841017): focus shifts to growth after strategic review and margin reset - AD HOC NEWS